Design, Characterization, and Lead Selection of Therapeutic miRNAs Targeting Huntingtin for Development of Gene Therapy for Huntington's Disease

Huntington's disease (HD) is a neurodegenerative disorder caused by accumulation of CAG expansions in the huntingtin (HTT) gene. Hence, decreasing the expression of mutated HTT (mtHTT) is the most upstream approach for treatment of HD. We have developed HTT gene-silencing approaches based on ex...

Full description

Bibliographic Details
Main Authors: Jana Miniarikova, Ilaria Zanella, Angelina Huseinovic, Tom van der Zon, Evelyn Hanemaaijer, Raygene Martier, Annemart Koornneef, Amber L Southwell, Michael R Hayden, Sander J van Deventer, Harald Petry, Pavlina Konstantinova
Format: Article
Language:English
Published: Elsevier 2016-01-01
Series:Molecular Therapy: Nucleic Acids
Subjects:
Online Access:http://www.sciencedirect.com/science/article/pii/S2162253117300987
id doaj-bfb13c6a50a649a182bd1d5204f6412a
record_format Article
spelling doaj-bfb13c6a50a649a182bd1d5204f6412a2020-11-24T22:48:07ZengElsevierMolecular Therapy: Nucleic Acids2162-25312016-01-015C10.1038/mtna.2016.7Design, Characterization, and Lead Selection of Therapeutic miRNAs Targeting Huntingtin for Development of Gene Therapy for Huntington's DiseaseJana Miniarikova0Ilaria Zanella1Angelina Huseinovic2Tom van der Zon3Evelyn Hanemaaijer4Raygene Martier5Annemart Koornneef6Amber L Southwell7Michael R Hayden8Sander J van Deventer9Harald Petry10Pavlina Konstantinova11Department of Research & Development, uniQure, Amsterdam, the NetherlandsDepartment of Research & Development, uniQure, Amsterdam, the NetherlandsDepartment of Research & Development, uniQure, Amsterdam, the NetherlandsDepartment of Research & Development, uniQure, Amsterdam, the NetherlandsDepartment of Research & Development, uniQure, Amsterdam, the NetherlandsDepartment of Research & Development, uniQure, Amsterdam, the NetherlandsDepartment of Research & Development, uniQure, Amsterdam, the NetherlandsCentre for Molecular Medicine and Therapeutics, University of British Columbia, Vancouver, CanadaCentre for Molecular Medicine and Therapeutics, University of British Columbia, Vancouver, CanadaDepartment of Gastroenterology and Hepatology, Leiden University Medical Center, Leiden, the NetherlandsDepartment of Research & Development, uniQure, Amsterdam, the NetherlandsDepartment of Research & Development, uniQure, Amsterdam, the NetherlandsHuntington's disease (HD) is a neurodegenerative disorder caused by accumulation of CAG expansions in the huntingtin (HTT) gene. Hence, decreasing the expression of mutated HTT (mtHTT) is the most upstream approach for treatment of HD. We have developed HTT gene-silencing approaches based on expression cassette-optimized artificial miRNAs (miHTTs). In the first approach, total silencing of wild-type and mtHTT was achieved by targeting exon 1. In the second approach, allele-specific silencing was induced by targeting the heterozygous single-nucleotide polymorphism (SNP) rs362331 in exon 50 or rs362307 in exon 67 linked to mtHTT. The miHTT expression cassette was optimized by embedding anti-HTT target sequences in ten pri-miRNA scaffolds and their HTT knockdown efficacy, allele selectivity, passenger strand activity, and processing patterns were analyzed in vitro. Furthermore, three scaffolds expressing miH12 targeting exon 1 were incorporated in an adeno-associated viral serotype 5 (AAV5) vector and their HTT knock-down efficiency and pre-miHTT processing were compared in the humanized transgenic Hu128/21 HD mouse model. Our data demonstrate strong allele-selective silencing of mtHTT by miSNP50 targeting rs362331 and total HTT silencing by miH12 both in vitro and in vivo. Ultimately, we show that HTT knock-down efficiency and guide strand processing can be enhanced by using different cellular pri-miRNA scaffolds.http://www.sciencedirect.com/science/article/pii/S2162253117300987adeno-associated virusgene silencinghumanized HD mouse modelHuntington's diseasetherapeutic microRNAs
collection DOAJ
language English
format Article
sources DOAJ
author Jana Miniarikova
Ilaria Zanella
Angelina Huseinovic
Tom van der Zon
Evelyn Hanemaaijer
Raygene Martier
Annemart Koornneef
Amber L Southwell
Michael R Hayden
Sander J van Deventer
Harald Petry
Pavlina Konstantinova
spellingShingle Jana Miniarikova
Ilaria Zanella
Angelina Huseinovic
Tom van der Zon
Evelyn Hanemaaijer
Raygene Martier
Annemart Koornneef
Amber L Southwell
Michael R Hayden
Sander J van Deventer
Harald Petry
Pavlina Konstantinova
Design, Characterization, and Lead Selection of Therapeutic miRNAs Targeting Huntingtin for Development of Gene Therapy for Huntington's Disease
Molecular Therapy: Nucleic Acids
adeno-associated virus
gene silencing
humanized HD mouse model
Huntington's disease
therapeutic microRNAs
author_facet Jana Miniarikova
Ilaria Zanella
Angelina Huseinovic
Tom van der Zon
Evelyn Hanemaaijer
Raygene Martier
Annemart Koornneef
Amber L Southwell
Michael R Hayden
Sander J van Deventer
Harald Petry
Pavlina Konstantinova
author_sort Jana Miniarikova
title Design, Characterization, and Lead Selection of Therapeutic miRNAs Targeting Huntingtin for Development of Gene Therapy for Huntington's Disease
title_short Design, Characterization, and Lead Selection of Therapeutic miRNAs Targeting Huntingtin for Development of Gene Therapy for Huntington's Disease
title_full Design, Characterization, and Lead Selection of Therapeutic miRNAs Targeting Huntingtin for Development of Gene Therapy for Huntington's Disease
title_fullStr Design, Characterization, and Lead Selection of Therapeutic miRNAs Targeting Huntingtin for Development of Gene Therapy for Huntington's Disease
title_full_unstemmed Design, Characterization, and Lead Selection of Therapeutic miRNAs Targeting Huntingtin for Development of Gene Therapy for Huntington's Disease
title_sort design, characterization, and lead selection of therapeutic mirnas targeting huntingtin for development of gene therapy for huntington's disease
publisher Elsevier
series Molecular Therapy: Nucleic Acids
issn 2162-2531
publishDate 2016-01-01
description Huntington's disease (HD) is a neurodegenerative disorder caused by accumulation of CAG expansions in the huntingtin (HTT) gene. Hence, decreasing the expression of mutated HTT (mtHTT) is the most upstream approach for treatment of HD. We have developed HTT gene-silencing approaches based on expression cassette-optimized artificial miRNAs (miHTTs). In the first approach, total silencing of wild-type and mtHTT was achieved by targeting exon 1. In the second approach, allele-specific silencing was induced by targeting the heterozygous single-nucleotide polymorphism (SNP) rs362331 in exon 50 or rs362307 in exon 67 linked to mtHTT. The miHTT expression cassette was optimized by embedding anti-HTT target sequences in ten pri-miRNA scaffolds and their HTT knockdown efficacy, allele selectivity, passenger strand activity, and processing patterns were analyzed in vitro. Furthermore, three scaffolds expressing miH12 targeting exon 1 were incorporated in an adeno-associated viral serotype 5 (AAV5) vector and their HTT knock-down efficiency and pre-miHTT processing were compared in the humanized transgenic Hu128/21 HD mouse model. Our data demonstrate strong allele-selective silencing of mtHTT by miSNP50 targeting rs362331 and total HTT silencing by miH12 both in vitro and in vivo. Ultimately, we show that HTT knock-down efficiency and guide strand processing can be enhanced by using different cellular pri-miRNA scaffolds.
topic adeno-associated virus
gene silencing
humanized HD mouse model
Huntington's disease
therapeutic microRNAs
url http://www.sciencedirect.com/science/article/pii/S2162253117300987
work_keys_str_mv AT janaminiarikova designcharacterizationandleadselectionoftherapeuticmirnastargetinghuntingtinfordevelopmentofgenetherapyforhuntingtonsdisease
AT ilariazanella designcharacterizationandleadselectionoftherapeuticmirnastargetinghuntingtinfordevelopmentofgenetherapyforhuntingtonsdisease
AT angelinahuseinovic designcharacterizationandleadselectionoftherapeuticmirnastargetinghuntingtinfordevelopmentofgenetherapyforhuntingtonsdisease
AT tomvanderzon designcharacterizationandleadselectionoftherapeuticmirnastargetinghuntingtinfordevelopmentofgenetherapyforhuntingtonsdisease
AT evelynhanemaaijer designcharacterizationandleadselectionoftherapeuticmirnastargetinghuntingtinfordevelopmentofgenetherapyforhuntingtonsdisease
AT raygenemartier designcharacterizationandleadselectionoftherapeuticmirnastargetinghuntingtinfordevelopmentofgenetherapyforhuntingtonsdisease
AT annemartkoornneef designcharacterizationandleadselectionoftherapeuticmirnastargetinghuntingtinfordevelopmentofgenetherapyforhuntingtonsdisease
AT amberlsouthwell designcharacterizationandleadselectionoftherapeuticmirnastargetinghuntingtinfordevelopmentofgenetherapyforhuntingtonsdisease
AT michaelrhayden designcharacterizationandleadselectionoftherapeuticmirnastargetinghuntingtinfordevelopmentofgenetherapyforhuntingtonsdisease
AT sanderjvandeventer designcharacterizationandleadselectionoftherapeuticmirnastargetinghuntingtinfordevelopmentofgenetherapyforhuntingtonsdisease
AT haraldpetry designcharacterizationandleadselectionoftherapeuticmirnastargetinghuntingtinfordevelopmentofgenetherapyforhuntingtonsdisease
AT pavlinakonstantinova designcharacterizationandleadselectionoftherapeuticmirnastargetinghuntingtinfordevelopmentofgenetherapyforhuntingtonsdisease
_version_ 1725679533200244736